Medizinische Universität Graz - Research portal

Go directly to the nagivation.
Go directly to the content.

Navigation/Search

Selected Publication:

Fitscha, P; Simmet, T; Peskar, BA; Reuter, H; Sinzinger, H; Rogatti, W; Tilsner, V.
Fibrinolytic activity, thrombocyte function and pharmacokinetics during intra-arterial or intravenous prostaglandin E1 infusion in patients with chronic arterial occlusive disease
Wien Klin Wochenschr. 1988; 100(14):477-481
Web of Science PubMed Google Scholar

Co-authors Med Uni Graz: Peskar Bernhard
Altmetrics:
Dimensions Citations:
Plum Analytics:
Abstract:: Monitoring various parameters of fibrinolytic activity in 6 patients with arterial occlusive disease during intra-arterial (i.a.) or intravenous (i.v.) prostaglandin (PG) E1 infusions indicated activation of the endogenous fibrinolytic system. However, due to the small number of patients not all test parameters revealed significant changes. None of the PGE1 infusion regimens used (1.25 or 2.5 ng/kg/min i.a. or 5 or 10 ng/kg/min i.v. for 120 min in each case) led to any significant change in various parameters checked for ex-vivo platelet function. In agreement with these data the radioimmunological determination of PGE1 in venous plasma did not reveal any significant rise. On the other hand, the circulating metabolite of PGE1, 15-keto-13, 14-dihydro-PGE1, reached plasma levels which correlated well with expected theoretical values taking the infusion rate into consideration. A potential mechanism by which even low plasma concentrations of PGE1 might affect platelet function in vivo is discussed.
Find related publications in this database (using NLM MeSH Indexing): Alprostadil - administration and dosage; Arterial Occlusive Diseases - drug therapy; Clinical Trials as Topic - drug therapy; Fibrinolysis - drug effects; Humans - drug effects; Infusions, Intra-Arterial - drug effects; Infusions, Intravenous - drug effects; Platelet Aggregation - drug effects